Adjunctive drug therapy for acute myocardial infarction, including beta-blockers and ACE inhibitors, is reviewed based on current evidence from published randomized trials and meta-analyses.
A review of evidence from randomized trials and meta-analyses regarding adjunctive drug therapies for acute myocardial infarction.
Despite improvement in primary prevention1 and treatment,2 acute myocardial infarction remains the chief cause of death in the United States and most developed countries. Almost half of all victims of myocardial infarction die before they reach the hospital.3 Of several hundred thousand patients hospitalized each year with acute myocardial infarction, 7 to 15 percent die during hospitalization and another 7 to 15 percent die during the following year.4 This article reviews the current evidence from published randomized trials (Table 1) and meta-analyses (Table 2) of adjunctive drug therapy with beta-adrenergic antagonists, angiotensin-converting–enzyme (ACE) inhibitors, nitrates, calcium-channel blockers, antiarrhythmic drugs, and . . .
Hennekens et al. (1996) conducted a review in Acute myocardial infarction. Adjunctive drug therapy (beta-adrenergic antagonists, ACE inhibitors, nitrates, calcium-channel blockers, antiarrhythmic drugs) was evaluated. Adjunctive drug therapy for acute myocardial infarction, including beta-blockers and ACE inhibitors, is reviewed based on current evidence from published randomized trials and meta-analyses.